Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
This study plans to assess the effectiveness of performance-based functional assessments (PBFAs) and cognitive assessments in diagnosing Alzheimer's disease in Hispanic/Latino populations. The information from this study will be analyzed with data from the Rocky Mountain Alzheimer's Disease Center Bio-AD study (NCT02612376).

Official Title
-----------------
Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease

Conditions
-----------------
Mild Cognitive Impairment, Healthy Controls

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons with age-related MCI or AD according to clinical diagnosis, consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria Community-dwelling controls Age > 55 years Have been enrolled and completed at least one visit in the Bio-AD study and consent to access their data (the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)) Have capacity to provide consent; capacity will be assessed at the time of consent Ability to complete baseline assessments Has informant (study partner) available to complete functional interviews/survey measures Exclusion Criteria: Presence of concomitant medical, neurological, or psychiatric illness or condition that in the opinion of the investigators would confound interpretation of study results. These include: Korsakoff encephalopathy; active substance abuse; hepatitis C; opportunistic brain infection; brain tumor; active neoplastic disease (skin tumors other than melanoma are not exclusionary; participants with stable prostate cancer may be included at the discretion of the project director); multiple sclerosis; history of clinically significant stroke; current evidence or history in the past 2 years of focal brain lesion, head injury with loss of consciousness in the past year, or DSM-5 criteria for any major psychiatric disorder, including psychosis, uncontrolled major depression, bipolar disorder, alcohol or substance abuse; blindness, deafness or any other disability which may prevent the participant from participating or cooperating in the protocol. Prisoners Any contraindication for MRI

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mild Cognitive Impairment (MCI)<br>Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria. Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376). | |
| Healthy Controls<br>Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA) | Measure independent functioning in everyday life for controls and individuals with MCI | 30 minutes | 
| Medication Management Ability Assessment | Measure independent management of medications in controls and individuals with MCI | 15 minutes | 
| Lawton iADL (instrumental activities of daily living) scale | Measure ability to perform instrumental activities of daily living in controls and individuals with MCI | 5 minutes |